Kelly Lisa 4
4 · VERTEX PHARMACEUTICALS INC / MA · Filed Feb 7, 2013
Insider Transaction Report
Form 4
Kelly Lisa
SVP, Human Resources
Transactions
- Award
Common Stock
2013-02-05$0.01/sh+10,166$102→ 25,382 total - Award
Employee Stock Option (right to buy)
2013-02-05+45,750→ 45,750 totalExercise: $45.11Exp: 2023-02-04→ Common Stock (45,750 underlying)
Holdings
- 1,965(indirect: By 401(k))
Common Stock
Footnotes (2)
- [F1]Stock grant under 2006 Stock and Option Plan, vesting on 2/5/2017, subject to (i) acceleration of 50% of shares upon (a) receiving filing confirmation for an NDA for a combination regimen that includes both ivacaftor and a corrector compound or (b) receiving filing confirmation for an sNDA that would increase the number of patients with CF eligible for ivacaftor monotherapy, and (ii) acceleration of 50% of shares upon (a) the announcement of proof-of-concept data for a drug candidate other than an HCV, cystic fibrosis, influenza or JAK3 inhibition drug candidate or (b) reaching a specified net sales level over a twelve month period for our CF products.
- [F2]Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/05/2013.